AbCellera Biologics Inc. (ABCL) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for AbCellera Biologics Inc. (ABCL): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 38/100 — a percentile rank of AbCellera Biologics Inc.’s fundamentals against Manufacturing peers, weakest on management. A quality ranking, not a price prediction.
| Market cap | $4.5B |
| P / S | 68.1× |
| EV / EBITDA | -21.4× |
| Gross margin | 100.0% |
| Operating margin | -340.3% |
| Net margin | -248.8% |
| Return on equity | -18.4% |
| ROIC | -24.3% |
| Revenue growth | 101.3% |
| Debt / equity | 0.0× |
| Dividend yield | 0.0% |
Is AbCellera Biologics Inc. overvalued? P/S looks overvalued vs its 5-year range; P/B looks overvalued vs its 5-year range.
Independent of the events above — derived from AbCellera Biologics Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact